The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

Publications

Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F

Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2012;18(1):39-41

Heresi GA, Farver CF, Stoller JK

Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature.

Respiration; international review of thoracic diseases. 2008;76(4):449-53

Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH

Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.

Leukemia & lymphoma. 2004;45(11):2321-5